Safety of Urate-Lowering Therapies. Managing the Risks to Gain the Benefits.

Rheumatic Disease Clinics of North America

Volumn 38, Issue 4, 2012, Pages 663-680

  Keenan, Robert T ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allopurinol; Febuxostat; Gout; Pelgoticase; Safety

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BENZBROMARONE; CAPTOPRIL; DIGOXIN; DIURETIC AGENT; FEBUXOSTAT; HYDROCORTISONE SODIUM SUCCINATE; LIVER ENZYME; MERCAPTOPURINE; METHYLPREDNISOLONE SODIUM SUCCINATE; PEGLOTICASE; PLACEBO; PROBENECID; SULFINPYRAZONE; URIC ACID; WARFARIN; XANTHINE OXIDASE INHIBITOR;

AGRANULOCYTOSIS; ANAPHYLAXIS; ARTHRALGIA; BACKACHE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; COST EFFECTIVENESS ANALYSIS; CUTANEOUS VASCULITIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRESS SYNDROME; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ERYTHEMA; FATIGUE; FLANK PAIN; FLUSHING; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GOUT; HEALTH CARE COST; HEART FAILURE; HLA MATCHING; HUMAN; HYPERURICEMIA; INFUSION RELATED REACTION; JOINT STIFFNESS; JOINT SWELLING; KIDNEY FAILURE; LEG PAIN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MEDICAL DECISION MAKING; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN ALLERGY; SKIN EXFOLIATION; STOMACH DISCOMFORT; THORAX PAIN; TOXIC HEPATITIS; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; URTICARIA; VASCULITIS; VOMITING;

ALLOPURINOL; COMORBIDITY; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; RISK FACTORS; THIAZOLES; URIC ACID;

EID: 84868341088     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.008     Document Type: Review

References (75)

1. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63:3136-3141.
2. Arromdee E., Michet C.J., Crowson C.S., et al. Epidemiology of gout: is the incidence rising?. J Rheumatol 2002, 29:2403-2406.
3. Weaver A.L. Epidemiology of gout. Cleve Clin J Med 2008, 75(Suppl 5):S9-12.
4. Driver J.A., Djousse L., Logroscino G., et al. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ 2008, 337:a2467.
5. Folsom A.R., Yatsuya H., Nettleton J.A., et al. Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol 2011, 57:1690-1696.
6. Choi H.K., Atkinson K., Karlson E.W., et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005, 165:742-748.
7. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116:894-900.
8. Pillinger M.H., Goldfarb D.S., Keenan R.T. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010, 68:199-203.
9. Keenan R.T., O'Brien W.R., Lee K.H., et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011, 124:155-163.
10. Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012, 125(7):679-687.e1.
11. Mikuls T.R., Farrar J.T., Bilker W.B., et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005, 64:267-272.
12. Riedel A.A., Nelson M., Wallace K., et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004, 10:308-314.
13. Wyngaarden J.B., Rundles R.W., Metz E.N. Allopurinol in the treatment of gout. Ann Intern Med 1965, 62:842-847.
14. Talbott J.H., Bishop C., Norcross B.M., et al. The clinical and metabolic effects of benemid in patients with gout. Trans Assoc Am Physicians 1951, 64:372-377.
15. Sarawate C.A., Patel P.A., Schumacher H.R., et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65.
16. Mikuls T.R., Curtis J.R., Allison J.J., et al. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006, 33:562-566.
17. Mikuls T.R., Farrar J.T., Bilker W.B., et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005, 44:1038-1042.
18. Sarawate C.A., Brewer K.K., Yang W., et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925-934.
19. Perez-Ruiz F., Calabozo M., Pijoan J.I., et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356-360.
20. Dal Pan G.J. Communicating the risks of medicine: time to move forward. Med Care 2012, 50:463-465.
21. Kongkaew C., Noyce P.R., Ashcroft D.M. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008, 42:1017-1025.
22. Khanna P.P., Perez-Ruiz F., Maranian P., et al. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011, 50:740-745.
23. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011, 71:1413-1439.
24. Wu E.Q., Forsythe A., Guerin A., et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther 2011, [Epub ahead of print].
25. Pacher P., Nivorozhkin A., Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006, 58:87-114.
26. Stocker S.L., Graham G.G., McLachlan A.J., et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011, 38:904-910.
27. Pennell D.J., Nunan T.O., O'Doherty M.J., et al. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet 1984, 1:463.
28. Samanta A., Burden A.C. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol. Lancet 1984, 1:679.
29. Ahmad S. Allopurinol and enalapril. Drug induced anaphylactic coronary spasm and acute myocardial infarction. Chest 1995, 108:586.
30. Stamp L.K., Taylor W.J., Jones P.B., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012, 64(8):2529-2536.
31. Khanna D., Fuldeore M.J., Meissner B.L., et al. The incidence of allopurinol hypersensitivity syndrome: a population perspective. Arthritis Rheum 2008, 60:S542.
32. Lang P.G. Severe hypersensitivity reactions to allopurinol. South Med J 1979, 72:1361-1368.
33. Tassaneeyakul W., Jantararoungtong T., Chen P., et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009, 19:704-709.
34. Dalbeth N., Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007, 20:391-395.
35. Lee H.Y., Ariyasinghe J.T., Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?. Singapore Med J 2008, 49:384-387.
36. Turnheim K., Krivanek P., Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999, 48:501-509.
37. Hung S.I., Chung W.H., Liou L.B., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005, 102:4134-4139.
38. Lonjou C., Borot N., Sekula P., et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99-107.
39. Kaniwa N., Saito Y., Aihara M., et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008, 9:1617-1622.
40. Kang H.R., Jee Y.K., Kim Y.S., et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011, 21:303-307.
41. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003, 17:397-414.
42. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
43. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of furosemide on renal excretion of oxypurinol and purine bases. Metabolism 2001, 50:241-245.
44. Stamp L.K., Barclay M.L., O'Donnell J.L., et al. Furosemide increases plasma oxypurinol without lowering serum urate-a complex drug interaction: implications for clinical practice. Rheumatology (Oxford) 2012, 51(9):1670-1676.
45. Stamp L.K., Barclay M.L., O'Donnell J.L., et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 2011, 90:392-398.
46. Emmerson B.T. The management of gout. N Engl J Med 1996, 334:445-451.
47. Emmerson B.T., Gordon R.B., Cross M., et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 1987, 26:445-449.
48. Dalbeth N., Kumar S., Stamp L., et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646-1650.
49. Vazquez-Mellado J., Morales E.M., Pacheco-Tena C., et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60:981-983.
50. Emmerson B.T., Hazelton R.A., Frazer I.H. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum 1988, 31:436-440.
51. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
52. Schumacher H.R., Becker M.A., Wortmann R.L., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540-1548.
53. Becker M.A., Schumacher H.R., Espinoza L.R., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63.
54. Takano Y., Hase-Aoki K., Horiuchi H., et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005, 76:1835-1847.
55. Keenan R.T., Pillinger M.H. Febuxostat: a new agent for lowering serum urate. Drugs Today (Barc) 2009, 45:247-260.
56. Mukoyoshi M., Nishimura S., Hoshide S., et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008, 38:496-510.
57. Effect of febuxostat on renal function in patients with gout and moderate to severe renal impairment. 2012. Available at: Accessed July 30, 2012. http://clinicaltrials.gov/ct2/show/NCT01082640%3Fterm%3Dfebuxostat%26rank%3D4.
58. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011, 38:1957-1959.
59. Ernst M.E., Fravel M.A. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther 2009, 31:2503-2518.
60. White W.B., Grady D., Giudice L.C., et al. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J 2012, 163:27-32.
61. Krystexxa (pegloticase): prescribing information 2012, Savient Pharmaceuticals, Inc, East Brunswick (NJ).
62. Sundy J.S., Ganson N.J., Kelly S.J., et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028.
63. Hershfield M.S., Roberts L.J., Ganson N.J., et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A 2010, 107:14351-14356.
64. Sundy J.S., Baraf H.S., Yood R.A., et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011, 306:711-720.
65. Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006, 47:373-380.
66. Sundy J.S., Becker M.A., Baraf H.S., et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008, 58:2882-2891.
67. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
68. Boger W.P., Strickland S.C. Probenecid (benemid); its uses and side-effects in 2,502 patients. AMA Arch Intern Med 1955, 95:83-92.
69. Cunningham R.F., Israili Z.H., Dayton P.G. Clinical pharmacokinetics of probenecid. Clin Pharm 1981, 6:135-151.
70. Reinders M.K., van Roon E.N., Jansen T.L., et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009, 68:51-56.
71. Probenecid prescribing information. 2012. Available at: Accessed June 23, 2012. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm%3Fsetid%3D5ca3dd4c-b8b4-4131-a066-214dabb2576f%23nlm34067-9.
72. Fam A.G. Gout in the elderly. Clinical presentation and treatment. Drugs Aging 1998, 13:229-243.
73. Robbins N., Koch S.E., Tranter M., et al. The history and future of probenecid. Cardiovasc Toxicol 2012, 12:1-9.
74. Allopurinol: drug information: Lexicomp; 2006. Available at: Accessed July 29, 2012. http://www.uptodate.com/crlsql/interact/frameset.jsp.
75. Uloric (febuxostat): prescribing information 2011, Takeda Pharmaceuticals American, Inc, Deerfield (IL).